Case Report

Liquid Levothyroxine Formulation Taken during Lunch in Italy: A Case Report and Review of the Literature

Carlo Cappelli, Ilenia Pirola, and Maurizio Castellano

Department of Clinical and Experimental Sciences, SSD Medicina Ad Indirizzo Endocrino-metabolico, University of Brescia, ASST Spedali Civili di Brescia, Brescia 25123, Italy

Correspondence should be addressed to Carlo Cappelli; carlo.cappelli@unibs.it

Received 10 June 2020; Revised 15 August 2020; Accepted 24 August 2020; Published 7 September 2020

Academic Editor: Suat Simsek

Copyright © 2020 Carlo Cappelli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Levothyroxine (L-T4) is among the most widely prescribed medications in the world, and it is considered by the World Health Organization an essential medicine for basic health care [1–3].

The first use of thyroid hormone for the treatment of hypothyroidism was documented in the 1890s, when Bettencourt and Serrano described a patient grafted with an ovine thyroid gland to treat severe hypothyroidism [4]. Synthetic formulations of thyroxine have been available for use since the 1950s although desiccated animal thyroid gland remained the mainstay of therapy until the 1970s [5].

In addition to sodium levothyroxine (L-T4) in tablet form, today various L-T4 formulations (soft-gel capsules and liquid solutions) are being used in most but not all countries for clinical use in the last years [6]. Approximately 60–90% of a tablet L-T4 dose is absorbed within 3 h of ingestion, and the absorption is maximal when it is taken on an empty stomach, reflecting the importance of gastric acidity in the process. Differently, many reports showed that liquid formulations circumvent gastric acidity, improving their absorption even if ingested with breakfast [7–11].

We described a young Italian man who took liquid levothyroxine formulation during lunch.

2. Case Presentation

A 31-year-old male patient was referred to our Department for hypothyroidism on 3 April 2018. His medical history was not significant. He suffered from Hashimoto’s thyroiditis and had been under replacement therapy with liquid
levothyroxine 75 mcg daily (Tirosint 75 mcg-IBSA®) for three years. Physical examination showed no abnormalities. He exhibited two thyroid hormonal profiles (TSH, fT4, and fT3) taken, respectively, in the previous fifteen days and 6 months by outpatient evaluation (Table 1). The patient underwent thyroid ultrasound that showed an atrophic gland with marked hypoechoic tissue, without nodules (Figure 1). During confirmation of the L-T4 replacement therapy, the patient stated that he was going to continue to “take liquid levothyroxine during (his) lunch every day.” The patient said that, only during the first year, he had taken liquid L-T4 at least 30 minutes before breakfast, while in the last two, he had been taking liquid L-T4 with a glass of water during his lunch “for convenience.” We recommended taking the medication correctly in the morning at least thirty minutes before breakfast and repeating TSH, fT4, and fT3 after three months. The patient was reassessed on 27 July. He was in good health. The thyroid hormonal profiles are reported in Table 1. No difference in TSH, fT4, and fT3 was observed compared to the values found when the patient took the medication during lunch. New examinations were performed in the same laboratory after 6 months; TSH, fT4, and fT3 were still superimposable with the previous values (Table 1).

3. Discussion

We described for the first time, a patient taking liquid L-T4 during lunch in Italy. There was no change in serum TSH level after changing the timing of L-T4 ingestion to at least 30 minutes before breakfast.

Until ten years ago, the only formulation available was the tablet. Replacement therapy has always been considered straightforward although different factors may interfere with intestinal absorption of L-T4, including food, dietary fibre, coffee, drugs, and gastrointestinal diseases [12]. For these reasons, current guidelines recommend that L-T4 should be taken in a fasting state at least 30 minutes before breakfast or at bedtime (at least three hours after the evening meal) because its absorption is maximised when it is taken on an empty stomach, reflecting the importance of gastric acidity in the absorption process. [13, 14]. Indeed, discordant results on timing of L-T4 administration with respect to main meal are reported [15, 16].

Ten years ago, pharmaceutical companies introduced new levothyroxine formulations (liquid and soft-gel capsules) promising improved absorption. This could be due to the fact that these formulations circumvent the phase of gastric dissolution, which is closely dependent on gastric pH. This is true for liquid formulations because the active ingredient is already dissolved in 85% glycerol and 96% ethanol. Cassio et al. showed that, for the first time in 2013, there is no full bioequivalence between drops and tablets, especially for infants with severe congenital hypothyroidism, suggesting that liquid form could be more effective and/or better absorbed than tablets [17]. The following year, our group observed by chance a series of euthyroid patients who wrongly took liquid L-T4 with coffee at breakfast; after changing the time of intake to 30 min before breakfast, no change in thyroid hormonal profile was observed. This feedback suggested that that liquid T4 can be taken orally at breakfast both with water and with coffee. Taking into account these data, we hypothesized that high temperatures (i.e., coffee temperature) do not alter the molecular properties or stability of L-T4 [10]. This was later clearly demonstrated by Bernareggi and colleagues [18]. Moreover, the TICO study, a double-blind placebo-controlled crossover trial, confirmed that liquid L-T4 can be ingested directly at breakfast, thus potentially improving therapeutic compliance [9], data recently confirmed in more than seven hundred patients [10].

Many other subsequent studies and observations have shown the significant superiority in terms of TSH normalization of the liquid formulation compared to tablets even in different subsets of patients, such as those with or without gastrointestinal malabsorption, submitted to bariatric surgery or taking multiple concomitant drugs [19–24]. Furthermore, the use of liquid L-T4 showed a significantly reduced variability in TSH values, both in young and older people, with a higher number of patients who remained euthyroid during follow-up [25, 26]. This is relevant for at least two reasons: firstly, the simultaneous reduction in risk of developing other disorders mainly associated, but not exclusive, with clinical or subclinical hyperthyroidism, such as atrial fibrillation, osteoporosis, and coronary heart disease [27, 28]; secondly, subjects with stable euthyroidism during replacement L-T4 therapy required fewer blood checks, with a predictable relative reduction in total health care expenditure [29, 30].

Finally, the possibility of taking levothyroxine treatment during breakfast improves quality of life [31] and significantly improves adherence to the treatment [27] as recently reported by two Italian surveys.

Differently from liquid solution, soft-gel capsules contain the drug dissolved in glycerin and enclosed in a gelatinous matrix. This structure should promise protection from variations in gastric pH. In agreement, in vitro research showed that the dissolution profile was more consistent than for tablets in the entire pH range after 60–120 minutes [32]. This has been confirmed in vivo by Fiorni et al., showing a total dissolution time of about 20 minutes [33]. Literature shows that this formulation improves the TSH profile in patients with impaired gastric secretion [34], taking pump inhibitors [35], with central hypothyroidism [36], in postmenopausal woman taking calcium supplements [37] and also a few minutes before breakfast with coffee [38], as compared to tablets. On the contrary, Di Donna et al. demonstrated that there was no difference in L-T4 requirement between soft-gel capsules and tablets in patients without malabsorption although the serum TSH was lower in patients taking soft-gel capsules [39]. To the best of our knowledge only one study, the “TITI” study evaluated whether a soft-gel capsule of L-T4 could also be ingested at breakfast, instead of liquid formulation. The study showed that both the liquid and soft-gel capsule formulations of L-T4 can be taken with breakfast although a significant decrease in fT4 and fT3 was observed 6 months after the switch from liquid to soft-gel capsules [40]. For these
reasons, the authors suggested that "liquid L-T4 would be the preferred formulation for patients in whom even small changes in fT4 and fT3 levels are to be avoided." Further studies are needed to clarify this important issue.

4. Conclusion

The new levothyroxine formulation should be preferred in case of malabsorption or potential malabsorption. Liquid formulation should be preferred due to the possibility of taking it during breakfast, which significantly improves the compliance of patients. Further studies are needed to evaluate the possibility of taking liquid L-T4 during lunch.

Data Availability

The data used to support the findings of the study are available on request.

Conflicts of Interest

The authors declare that there are no conflicts of interest.

Acknowledgments

The authors would like to thank the patient for agreeing to participate in this case report and for his contribution to expanding medical knowledge on this topic.

References

[1] F. R. Ernst, P. Barr, R. Elmor et al., “The economic impact of levothyroxine dose adjustments: the CONTROL HE study,” Clinical Drug Investigation, vol. 37, no. 1, pp. 71–83, 2017.
[2] A. V. Fuentes, M. D. Pineda, and K. C. N. Venkata, “Comprehension of top 200 prescribed drugs in the US as a resource for pharmacy teaching, training and practice,” Pharmacy (Basel), vol. 14, no. 6, p. 43, 2018.
[3] World Health Organization, “WHO model list of essential medicines,” 2019, http://apps.who.int/iris/bitstream/handle/10665/273826/EML-20-eng.pdf?ua=1.
[4] A.-M. Betencourt and J.-A. Serrano, Un Cas De Myxoedeme (Cachexie Pachydermique) Traite´ Par La Greffe Hypoder- mique Du Corps Thy¨oı¨de D’un Mouton, Congres de l’Association Francaise pour l’Avancement des Sciences, Limoges, France, 1890.
[5] B. Bryan, “Levothyroxine: from sheep thyroid injections to synthetic formulations,” The Pharmaceutical Journal, vol. 291, p. 90, 2013.
[6] B. Biondi and L. Wartofsky, “Treatment with thyroid hor- mone,” Endocrine Reviews, vol. 35, no. 3, pp. 433–512, 2014.
[7] P. Trimbo, L. Scappaticcio, A. De Bellis et al., “Different formulations of levothyroxine for treating hypothyroidism: a real-life study,” International Journal of Endocrinology, vol. 2020, Article ID 4524759, 5 pages, 2020.
[8] M. Castellana, C. Castellana, L. Giovanella, and P. Trimbo, “Prevalence of gastrointestinal disorders having an impact on tablet levothyroxine absorption: should this formulation still be considered as the first-line therapy?” Endocrine, vol. 67, no. 2, pp. 281–290, 2020.
[9] C. Cappelli, I. Pirola, L. Daffini et al., “A double-blind pla-cebo-controlled trial of liquid thyroxine ingested at breakfast: results of the TICO study,” Thyroid, vol. 26, no. 2, pp. 197–202, 2016.
[10] I. Pirola, E. Gandossi, D. Brancato et al., “TSH evaluation in hypothyroid patients assuming liquid levothyroxine at breakfast or 30 min before breakfast,” Journal of Endocrinological Investigation, vol. 41, no. 11, pp. 1301–1306, 2018.
[11] C. Cappelli, I. Pirola, E. Gandossi, A. Formenti, and M. Castellano, “Oral liquid levothyroxine treatment at breakfast: a mistake?” European Journal of Endocrinology, vol. 170, no. 1, pp. 95–99, 2013.
[12] A. M. Formenti, I. Daffini, I. Pirola, E. Gandossi, A. Cristiano, and C. Cappelli, “Liquid levothyroxine and its potential use,” Hormones, vol. 14, no. 2, pp. 183–189, 2015.
[13] J. Jonklaas, A. C. Bianco, A. J. Bauer et al., “Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replace- ment,” Thyroid, vol. 24, no. 12, pp. 1670–1751, 2014.
[14] R. Guglielmi, A. Frasoldati, M. Zini et al., “Italian association of clinical endocrinologists statement-replacement therapy

Table 1: Thyroid function tests while taking liquid levothyroxine during lunch and before breakfast at the same daily dose.

|                      | Liquid L-T4 (75 mcg/die) taken during lunch | Liquid L-T4 (75 mcg/die) taken 30 minutes before breakfast |
|----------------------|-------------------------------------------|----------------------------------------------------------|
|                      | 6 months before evaluation | 15 days before evaluation | After 3 months from evaluation | After 9 months from evaluation |
| TSH, mIU/L            | 1.71                        | 1.69                        | 1.80                        | 1.75                        |
| (0.27–4.2)           |                            |                            |                             |                             |
| fT4, pg/ml (8.0–19.0) | 15.7                       | 15.3                       | 15.9                       | 15.6                       |
| fT3, pg/ml (2.4–4.7)  | 3.3                        | 3.1                        | 3.4                        | 3.3                        |

Figure 1: Thyroid ultrasound revealed an atrophic gland without nodules.
for primary hypothyroidism: a brief guide for clinical practice," *Endocrine Practice*, vol. 22, no. 11, pp. 1319–1326, 2016.

[15] T.-G. Bach-Huynh, B. Nayak, J. Loh, S. Soldin, and J. Jonklaas, “Timing of levothyroxine administration affects serum thyrotropin concentration,” *The Journal of Clinical Endocrinology & Metabolism*, vol. 94, no. 10, pp. 3905–3912, 2009.

[16] M. Skelin, T. Luciani, A.-M. Liberati-Cizmek et al., “Effect of timing of levothyroxine administration on the treatment of hypothyroidism: a three-period crossover randomized study,” *Endocrine*, vol. 62, no. 2, pp. 432–439, 2018.

[17] A. Cassio, S. Monti, A. Rizzello et al., “Comparison between liquid and tablet formulations of levothyroxine in the initial treatment of congenital hypothyroidism,” *The Journal of Pediatrics*, vol. 162, no. 6, pp. 1264–1269, 2013.

[18] A. Bernareggi, E. Grata, M. Pinorini, and A. Conti, “Oral liquid formulation of levothyroxine is stable in breakfast beverages and may improve thyroid patient compliance,” *Pharmaceutics*, vol. 5, no. 4, pp. 621–633, 2013.

[19] P. Fallahi, S. M. Ferrari, and A. Antonelli, “Oral L-thyroxine liquid versus tablet in patients with hypothyroidism without malabsorption: a prospective study,” *Endocrine*, vol. 52, no. 3, pp. 597–601, 2016.

[20] S. Benvenega, F. Di Bari, and R. Vita, “Untreated hypothyroidism due to calcium or iron supplementation corrected by oral liquid levothyroxine,” *Endocrine*, vol. 56, no. 1, pp. 138–145, 2017.

[21] P. Fallahi, S. M. Ferrari, I. Ruffilli, and A. Antonelli, “Reversible normalisation of serum TSH levels in patients with autoimmune atrophic gastritis who received L-T4 in tablet form after switching to an oral liquid formulation: a case series,” *BMC Gastroenterology*, vol. 24, no. 16, p. 22, 2016.

[22] P. Fallahi, S. M. Ferrari, S. Camastra et al., “TSH normalisation in bariatric surgery patients after the switch from L-thyroxine in tablet to an oral liquid formulation,” *Obesity Surgery*, vol. 27, no. 1, pp. 78–82, 2017.

[23] I. Pirola, A. M. Formenti, E. Gandossi et al., “Oral liquid L-thyroxine (L-t4) may be better absorbed compared to L-T4 tablets following bariatric surgery,” *Obesity Surgery*, vol. 23, no. 9, pp. 1493–1496, 2013.

[24] R. Vita, F. Di Bari, and S. Benvenega, “Oral liquid levothyroxine solves the problem of tablet levothyroxine malabsorption due to concomitant intake of multiple drugs,” *Expert Opinion on Drug Delivery*, vol. 14, no. 4, pp. 467–472, 2017.

[25] R. Negro, R. Valcavi, D. Agrimi, and K. Toulis, “Levo-thyroxine liquid solution versus tablet for replacement treatment in hypothyroid patients,” *Endocrine Practice*, vol. 20, no. 9, pp. 901–906, 2014.

[26] C. Cappelli, I. Pirola, L. Daffini, E. Gandossi, B. Agosti, and M. Castellano, “Thyroid hormonal profile in elderly patients treated with two different levothyroxine formulations: a single institute survey,” *European Geriatric Medicine*, vol. 5, no. 6, pp. 382–385, m2014.

[27] B. Biondi, “Natural history, diagnosis and management of subclinical thyroid dysfunction,” *Best Practice & Research Clinical Endocrinology & Metabolism*, vol. 26, no. 4, pp. 431–446, 2012.

[28] T. Collet, J. Gussekloo, D. C. Bauer et al., “Thyroid studies collaboration, subclinical hyperthyroidism and the risk of coronary heart disease and mortality,” *Archives of Internal Medicine*, vol. 172, no. 10, pp. 799–809, 2012.

[29] R. Ferrara, V. Lentile, V. Arcoraci et al., “Treatment pattern and frequency of serum TSH measurement in users of different levothyroxine formulations: a population-based study during the years 2009–2015,” *Endocrine*, vol. 58, no. 1, pp. 143–152, 2017.

[30] R. Guglielmi, F. Grimaldi, R. Negro et al., “Shift from levothyroxine tablets to liquid formulation at breakfast improves quality of life of hypothyroid patients,” *Endocrine, Metabolic & Immune Disorders - Drug Targets*, vol. 18, no. 3, pp. 235–240, 2018.

[31] C. Cappelli, R. Castello, F. Marin et al., “Adherence to levothyroxine treatment among patients with hypothyroidism: a northeastern Italian survey,” *Frontiers in Endocrinology*, vol. 23, no. 9, pp. 699–701, 2018.

[32] D. Pabl, F. Akhlaghi, and H. Zia, “A comparative pH-dis-solution profile study of selected commercial levothyroxine products using inductively coupled plasma mass spectrometry,” *European Journal of Pharmaceutics and Biopharmaceutics*, vol. 72, no. 1, pp. 105–110, 2009.

[33] G. Fiorini, D. Ribichini, R. Pasquali, and D. Vaira, “In vivo dissolution of levothyroxine soft gel capsules,” *Internal and Emergency Medicine*, vol. 11, no. 8, pp. 1151–1152, 2016.

[34] M. G. Santaguida, C. Virili, S. C. D. Duca et al., “Thyroxine softgel capsule in patients with gastric-related T4 malabsorption,” *Endocrine*, vol. 49, no. 1, pp. 51–57, 2015.

[35] R. Vita and S. Benvenega, “Tablet levothyroxine (L-T4) malabsorption induced by proton pump inhibitor; a problem that was solved by switching to L-T4 in soft gel capsule,” *Endocrine Practice*, vol. 20, no. 3, pp. 38–41, 2014.

[36] S. Benvenega, G. Capodicasa, and S. Perelli, “L-Thyroxine in an oral liquid or softgel formulation ensures more normal serum levels of free T4 in patients with central hypothyroidism,” *Frontiers in Endocrinology*, vol. 8, no. 321, pp. 1–6, 2017.

[37] E. Morini, A. Catalano, A. Lasco, N. Morabito, and S. Benvenega, “In thyroxine-replaced hypothyroid postmenopausal women under simultaneous calcium supplementation, switch to oral liquid or softgel capsule L-thyroxine ensures lower serum TSH levels and favorable effects on blood pressure, total choles terolemia and glycemia,” *Endocrine*, vol. 65, no. 3, pp. 569–579, 2019.

[38] R. Vita, G. Saraceno, F. Trimarchi, and S. Benvenega, “A novel formulation of L-thyroxine (L-T4) reduces the problem of L-T4 malabsorption by coffee observed with traditional tablet formulations,” *Endocrine*, vol. 43, no. 1, pp. 154–160, 2013.

[39] V. Di Donna, R. M. Paragliola, C. de Waure, G. Papi, A. Pontecorvi, and S. M. Corsello, “Is levothyroxine re-quired the same for tablet and softgel formulations?” *Endocrine*, vol. 59, no. 2, pp. 431–446, 2018.

[40] C. Cappelli, I. Pirola, E. Gandossi et al., “Thyroid hormone profile in patients ingesting soft gel capsule or liquid levothyroxine formulations with breakfast,” *International Journal of Endocrinology*, vol. 2016, Article ID 9043450, 5 pages, 2016.